VENUS REMEDIES | ALEMBIC | VENUS REMEDIES/ ALEMBIC |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -15.9 | 65.2 | - | View Chart |
P/BV | x | 1.1 | 5.6 | 18.9% | View Chart |
Dividend Yield | % | 0.0 | 0.2 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VENUS REMEDIES Mar-18 |
ALEMBIC Mar-18 |
VENUS REMEDIES/ ALEMBIC |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 72 | 174.9% | |
Low | Rs | 61 | 34 | 180.2% | |
Sales per share (Unadj.) | Rs | 301.8 | 4.7 | 6,420.3% | |
Earnings per share (Unadj.) | Rs | -24.9 | 6.1 | -407.5% | |
Cash flow per share (Unadj.) | Rs | 2.5 | 6.2 | 40.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0.20 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 293.3 | 40.7 | 721.3% | |
Shares outstanding (eoy) | m | 12.34 | 267.03 | 4.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 0.3 | 11.3 | 2.8% | |
Avg P/E ratio | x | -3.8 | 8.7 | -43.3% | |
P/CF ratio (eoy) | x | 36.7 | 8.5 | 433.4% | |
Price / Book Value ratio | x | 0.3 | 1.3 | 24.5% | |
Dividend payout | % | 0 | 3.3 | 0.0% | |
Avg Mkt Cap | Rs m | 1,154 | 14,139 | 8.2% | |
No. of employees | `000 | 0.9 | NA | - | |
Total wages/salary | Rs m | 393 | 207 | 189.5% | |
Avg. sales/employee | Rs Th | 4,026.1 | NM | - | |
Avg. wages/employee | Rs Th | 425.0 | NM | - | |
Avg. net profit/employee | Rs Th | -331.8 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,724 | 1,255 | 296.7% | |
Other income | Rs m | 23 | 370 | 6.1% | |
Total revenues | Rs m | 3,747 | 1,625 | 230.5% | |
Gross profit | Rs m | 395 | 111 | 355.4% | |
Depreciation | Rs m | 338 | 38 | 895.0% | |
Interest | Rs m | 354 | 2 | 20,841.2% | |
Profit before tax | Rs m | -275 | 442 | -62.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 1,212 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 32 | 24 | 131.9% | |
Profit after tax | Rs m | -307 | 1,630 | -18.8% | |
Gross profit margin | % | 10.6 | 8.9 | 119.8% | |
Effective tax rate | % | -11.5 | 5.4 | -211.7% | |
Net profit margin | % | -8.2 | 129.8 | -6.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,638 | 1,867 | 141.3% | |
Current liabilities | Rs m | 2,305 | 591 | 389.8% | |
Net working cap to sales | % | 8.9 | 101.6 | 8.8% | |
Current ratio | x | 1.1 | 3.2 | 36.2% | |
Inventory Days | Days | 135 | 94 | 143.7% | |
Debtors Days | Days | 46 | 74 | 63.0% | |
Net fixed assets | Rs m | 4,871 | 1,791 | 272.0% | |
Share capital | Rs m | 123 | 534 | 23.1% | |
"Free" reserves | Rs m | 3,496 | 10,324 | 33.9% | |
Net worth | Rs m | 3,619 | 10,858 | 33.3% | |
Long term debt | Rs m | 1,374 | 41 | 3,335.9% | |
Total assets | Rs m | 7,509 | 11,591 | 64.8% | |
Interest coverage | x | 0.2 | 260.9 | 0.1% | |
Debt to equity ratio | x | 0.4 | 0 | 10,008.1% | |
Sales to assets ratio | x | 0.5 | 0.1 | 458.0% | |
Return on assets | % | 0.6 | 14.1 | 4.5% | |
Return on equity | % | -8.5 | 15.0 | -56.5% | |
Return on capital | % | 1.6 | 15.2 | 10.4% | |
Exports to sales | % | 0 | 1.5 | 0.0% | |
Imports to sales | % | 13.9 | 21.0 | 66.1% | |
Exports (fob) | Rs m | NA | 19 | 0.0% | |
Imports (cif) | Rs m | 517 | 263 | 196.1% | |
Fx inflow | Rs m | 0 | 19 | 0.0% | |
Fx outflow | Rs m | 517 | 264 | 195.8% | |
Net fx | Rs m | -517 | -244 | 211.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 514 | 236 | 218.2% | |
From Investments | Rs m | -123 | -224 | 55.0% | |
From Financial Activity | Rs m | -387 | -27 | 1,455.3% | |
Net Cashflow | Rs m | 4 | -15 | -28.4% |
Indian Promoters | % | 32.9 | 64.0 | 51.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 0.2 | 90.0% | |
FIIs | % | 0.6 | 9.7 | 6.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 66.4 | 26.1 | 254.4% | |
Shareholders | 20,121 | 54,701 | 36.8% | ||
Pledged promoter(s) holding | % | 36.4 | 0.0 | - |
Compare VENUS REMEDIES With: WOCKHARDT J.B.CHEMICALS PROCTER & GAMBLE HEALTH BIOCON FULFORD INDIA
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets ended on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 375 points (up 0.8%).
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More